# Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic.

> **NCT04671589** · PHASE4 · UNKNOWN · sponsor: **Mabaret Al-Asafara Hospitals** · enrollment: 48 (estimated)

## Conditions studied

- Drug Toxicity

## Interventions

- **DRUG:** Meropenem Injection

## Key facts

- **NCT ID:** NCT04671589
- **Lead sponsor:** Mabaret Al-Asafara Hospitals
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06
- **Primary completion:** 2022-06
- **Final completion:** 2022-12
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04671589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04671589, "Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04671589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*